HGK Asset Management Inc. Purchases Shares of 1,595 Zimmer Biomet Holdings, Inc. (ZBH)

HGK Asset Management Inc. purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,595 shares of the medical equipment provider’s stock, valued at approximately $205,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bronfman E.L. Rothschild L.P. lifted its position in shares of Zimmer Biomet Holdings by 25.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 167 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Zimmer Biomet Holdings by 2.7% during the 1st quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Zimmer Biomet Holdings by 20.8% during the 1st quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares during the last quarter. IHT Wealth Management LLC lifted its position in shares of Zimmer Biomet Holdings by 28.4% during the 1st quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares during the last quarter. Finally, Sandy Spring Bank lifted its position in shares of Zimmer Biomet Holdings by 1.7% during the 1st quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 20 shares during the last quarter. 85.48% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have recently commented on the company. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $140.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Wells Fargo & Company reissued a “market weight” rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Jefferies Group LLC reissued a “buy” rating and set a $148.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, June 30th. Piper Jaffray Companies reissued a “buy” rating and set a $135.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $137.00 price objective on Zimmer Biomet Holdings and gave the stock a “buy” rating in a report on Friday, July 28th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $136.75.

In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.07% of the company’s stock.

Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 116.43 on Wednesday. Zimmer Biomet Holdings, Inc. has a 52-week low of $95.63 and a 52-week high of $133.49. The company has a market capitalization of $23.54 billion, a price-to-earnings ratio of 33.16 and a beta of 1.21. The company’s 50-day moving average price is $116.25 and its 200 day moving average price is $120.83.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. During the same quarter in the prior year, the firm posted $2.02 earnings per share. Zimmer Biomet Holdings’s quarterly revenue was up 1.1% on a year-over-year basis. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a yield of 0.82%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/09/13/hgk-asset-management-inc-purchases-shares-of-1595-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply